It’s very important to diagnose malignant pleural
mesothelioma at the onset of the stage if patients want only the best outcome.
And to hasten the benefits of early-stage mesothelioma diagnosis, researchers
are working hard to come up with a reliable yet non-invasive procedures to
identify the existence of mesothelioma symptoms.
An article published in the BMC Cancer journal reports of a
Japan-based research which assessed the the “usefulness of the blood protein
HMGB1 as a prognostic marker for mesothelioma,” reports AboutMesothelioma.net.
The research employed 106 participants who were exposed to
asbestos at a certain point of their lives. After examining their blood
samples, 61 individuals were found positive of malignant pleural mesothelioma,
while 45 were diagnosed with non-malignant asbestos-related disease, including
asbestosis, which is the scarring of the lungs.
The researchers also examined the presence and rate of HMGB1
molecules. HMGB1 is a type of protein. It is naturally-occurring in human cells
and is responsible for inflammation, cell reproduction and cell migration.
Patients with malignant pleural mesothelioma were found to
have a high level of protein in their blood, compared to patients with
non-malignant asbestos disease.
According to the researchers, high blood levels of HMGB1 show
signs of mesothelioma. They concluded that there is a significant correlation
between levels of HMBG1 and patient survival. This makes the protein very
helpful in determining a patient’s prognosis. To date, mesothelin is best
indicator of malignant pleural mesothelioma in blood tests.
No comments:
Post a Comment